CO2018011633A2 - 6-aminopiridin-3-il tiazoles como moduladores de rorγt - Google Patents
6-aminopiridin-3-il tiazoles como moduladores de rorγtInfo
- Publication number
- CO2018011633A2 CO2018011633A2 CONC2018/0011633A CO2018011633A CO2018011633A2 CO 2018011633 A2 CO2018011633 A2 CO 2018011633A2 CO 2018011633 A CO2018011633 A CO 2018011633A CO 2018011633 A2 CO2018011633 A2 CO 2018011633A2
- Authority
- CO
- Colombia
- Prior art keywords
- aminopyridin
- thiazoles
- rorγt
- syndrome
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Image Processing (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
RESUMEN La presente invención comprende compuestos de la Fórmula (I) en donde: A1, A2, A3, A4, A5, R1 y R2 se definen en la especificación. La invención comprende, además, un método para tratar o mejorar un síndrome, trastorno o enfermedad, en donde el síndrome, trastorno o enfermedad son artritis reumatoide o soriasis. La invención comprende, además, un método para modular la actividad de RORγt en un mamífero por medio de la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de la Fórmula I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662328074P | 2016-04-27 | 2016-04-27 | |
PCT/US2017/029531 WO2017189661A1 (en) | 2016-04-27 | 2017-04-26 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORγT |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018011633A2 true CO2018011633A2 (es) | 2018-11-13 |
Family
ID=59215941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0011633A CO2018011633A2 (es) | 2016-04-27 | 2018-10-29 | 6-aminopiridin-3-il tiazoles como moduladores de rorγt |
Country Status (26)
Country | Link |
---|---|
US (5) | US10975068B2 (es) |
EP (1) | EP3448856B1 (es) |
JP (1) | JP6893218B2 (es) |
KR (1) | KR20180135962A (es) |
CN (1) | CN109415358B (es) |
AR (1) | AR108344A1 (es) |
AU (1) | AU2017255525A1 (es) |
BR (1) | BR112018071942A2 (es) |
CA (1) | CA3022318A1 (es) |
CL (1) | CL2018003044A1 (es) |
CO (1) | CO2018011633A2 (es) |
CR (1) | CR20180505A (es) |
EA (1) | EA036318B1 (es) |
EC (1) | ECSP18088146A (es) |
ES (1) | ES2906258T3 (es) |
IL (1) | IL262381A (es) |
MA (1) | MA44772A (es) |
MX (1) | MX2018013143A (es) |
NI (1) | NI201800109A (es) |
PE (1) | PE20190150A1 (es) |
PH (1) | PH12018502209A1 (es) |
SG (1) | SG11201809162XA (es) |
SV (1) | SV2018005772A (es) |
TW (1) | TW201803869A (es) |
UY (1) | UY37213A (es) |
WO (1) | WO2017189661A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為RORγT調節劑之6-胺基吡啶-3-基噻唑 |
AU2019234541A1 (en) | 2018-03-12 | 2020-10-15 | Escalier Biosciences B.V. | Spirocyclic ROR-gamma modulators |
JP2021517563A (ja) * | 2018-03-12 | 2021-07-26 | エスカリア バイオサイエンシーズ,ビーブイ | 二環式RORγモジュレーター |
ES2929140T3 (es) | 2018-06-18 | 2022-11-25 | Janssen Pharmaceutica Nv | Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat |
WO2019244001A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of roryt |
US10975037B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of RORγt |
CN112292373A (zh) * | 2018-06-18 | 2021-01-29 | 詹森药业有限公司 | 作为RORγt的调节剂的吡啶基吡唑类 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL91418A (en) | 1988-09-01 | 1997-11-20 | Rhone Poulenc Agrochimie | (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them |
WO1996003392A1 (en) | 1994-07-27 | 1996-02-08 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
AU2002246397B2 (en) | 2001-04-16 | 2005-03-24 | Tanabe Seiyaku Co., Ltd. | Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence |
HUP0401160A3 (en) | 2001-08-13 | 2008-01-28 | Janssen Pharmaceutica Nv | 2,4,5-trisubstituted thiazolyl derivatives having antiinflammatory activity, process for their preparation and pharmaceutical compositions containing them |
US20050014805A1 (en) | 2001-10-12 | 2005-01-20 | Chenzhi Zhang | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
WO2006087355A1 (en) | 2005-02-16 | 2006-08-24 | Solvay Pharmaceuticals B.V. | 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators |
WO2006124687A1 (en) | 2005-05-12 | 2006-11-23 | University Of Medicine And Dentistry Of New Jersey | Opioid receptor subtype-selective agents |
US8455658B2 (en) | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
WO2008064317A1 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Lipophilic opioid receptor active compounds |
WO2008064318A2 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Peripheral opioid receptor active compounds |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
ES2567183T3 (es) | 2008-07-17 | 2016-04-20 | Bayer Cropscience Ag | Compuestos heterocíclicos como pesticidas |
TWI548411B (zh) | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
UA110097C2 (uk) | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
CN102762534A (zh) | 2009-09-18 | 2012-10-31 | 扎里卡斯药品有限公司 | 作为钙通道阻断剂的芳基砜衍生物 |
AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
US9492439B2 (en) | 2010-03-11 | 2016-11-15 | New York University | Amido compounds as RORγt modulators and uses thereof |
WO2011112264A1 (en) | 2010-03-11 | 2011-09-15 | New York University | Compounds as rorϒt modulators and uses thereof |
WO2011115892A1 (en) | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
US9505798B2 (en) | 2010-11-29 | 2016-11-29 | New York University | Steroid compounds as RORyt modulators and uses thereof |
US9500649B2 (en) | 2010-12-28 | 2016-11-22 | Arkray, Inc. | Analytical tool and method for determining a condition of an oral cavity |
US9012651B2 (en) | 2011-03-24 | 2015-04-21 | Abbvie Inc. | TRPV3 modulators |
US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
WO2012174362A1 (en) | 2011-06-17 | 2012-12-20 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
EP2738170B1 (en) | 2011-07-29 | 2017-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2013029338A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
KR20140072090A (ko) | 2011-09-09 | 2014-06-12 | 뉴욕 유니버시티 | RORγt 조정제로서의 아미도 화합물 및 이의 용도 |
JP5918859B2 (ja) | 2011-12-02 | 2016-05-18 | フェネックス ファーマシューティカルス アーゲー | オーファン核内受容体RARに関連するオーファン受容体−ガンマ(RORγ、NR1F3)活性の調整剤としての、慢性の炎症性疾患および自己免疫性疾患を治療するためのピロロカルボキサミド |
US20130190356A1 (en) | 2011-12-22 | 2013-07-25 | Genentech, Inc. | Benzyl sulfonamide derivatives as rorc modulators |
UA117913C2 (uk) * | 2012-05-31 | 2018-10-25 | Фінекс Фармас'Ютікалс Аг | КАРБОКСАМІД- АБО СУЛЬФОНАМІДЗАМІЩЕНІ ТІАЗОЛИ ТА СПОРІДНЕНІ ПОХІДНІ ЯК МОДУЛЯТОРИ ОРФАНОВОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
EP2931281B1 (en) | 2012-12-12 | 2018-01-17 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase inhibitors |
WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
CN105308037B (zh) | 2013-06-04 | 2017-09-19 | 阿克图拉姆生命科学股份公司 | 三唑化合物及其作为γ分泌酶调节剂的用途 |
CN105705501B (zh) | 2013-09-09 | 2019-04-19 | 百时美施贵宝公司 | RORγ调节剂 |
US20150072890A1 (en) | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
CN105555768B (zh) | 2013-09-20 | 2018-10-16 | 百时美施贵宝公司 | RORγ调节剂 |
AU2014334616A1 (en) | 2013-10-15 | 2016-04-28 | Janssen Pharmaceutica Nv | Quinolinyl modulators of RORyt |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
ES2708434T3 (es) * | 2013-10-15 | 2019-04-09 | Janssen Pharmaceutica Nv | Moduladores de RORyt de un grupo quinolinil unido a un grupo heteroaril |
AU2014359324B2 (en) | 2013-12-05 | 2019-02-21 | Lead Pharma Holding B.V. | ROR gamma (RORy) modulators |
US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
ES2704460T3 (es) | 2014-01-06 | 2019-03-18 | Bristol Myers Squibb Co | Moduladores de ROR gamma de ciclohexilsulfona |
US9771320B2 (en) | 2014-01-06 | 2017-09-26 | Bristol-Myers Squibb Company | Carbocyclic sulfone RORγ modulators |
JP6530764B2 (ja) | 2014-01-06 | 2019-06-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | RORγ調節因子としてのピロリジニルスルホン誘導体およびその使用 |
ES2705400T3 (es) | 2014-01-06 | 2019-03-25 | Bristol Myers Squibb Co | Sulfonas heterocíclicas como moduladores de ROR gamma |
TWI659019B (zh) | 2014-02-28 | 2019-05-11 | 日商帝人製藥股份有限公司 | 吡唑醯胺衍生物 |
WO2015139619A1 (zh) * | 2014-03-18 | 2015-09-24 | 北京韩美药品有限公司 | 作为RORγ调节剂的化合物 |
CA2942871A1 (en) | 2014-03-27 | 2015-10-01 | Piramal Enterprises Limited | Ror-gamma modulators and uses thereof |
CN103833672A (zh) | 2014-03-28 | 2014-06-04 | 中国药科大学 | 一种n-丁基-5-苯基噻唑-4-甲酰胺类衍生物的制备方法 |
EP3192791A4 (en) | 2014-09-11 | 2018-03-28 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
JOP20200117A1 (ar) * | 2014-10-30 | 2017-06-16 | Janssen Pharmaceutica Nv | كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t |
CN108064224B (zh) * | 2014-10-30 | 2022-03-29 | 詹森药业有限公司 | 作为Rorγt的调节剂的酰胺取代的噻唑 |
JP6661630B2 (ja) | 2014-10-30 | 2020-03-11 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγtのモジュレーターとしてのチアゾール |
TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為RORγT調節劑之6-胺基吡啶-3-基噻唑 |
AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
JP2020059651A (ja) | 2016-12-26 | 2020-04-16 | 科研製薬株式会社 | ピラゾール誘導体及びそれを含有する医薬 |
FR3065000A1 (fr) | 2017-04-06 | 2018-10-12 | Galderma Research & Development | Derives pyrazoles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
US10975037B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of RORγt |
CN112292373A (zh) | 2018-06-18 | 2021-01-29 | 詹森药业有限公司 | 作为RORγt的调节剂的吡啶基吡唑类 |
WO2019244001A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of roryt |
ES2929140T3 (es) | 2018-06-18 | 2022-11-25 | Janssen Pharmaceutica Nv | Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat |
-
2017
- 2017-04-25 TW TW106113710A patent/TW201803869A/zh unknown
- 2017-04-26 SG SG11201809162XA patent/SG11201809162XA/en unknown
- 2017-04-26 CA CA3022318A patent/CA3022318A1/en active Pending
- 2017-04-26 CN CN201780040332.4A patent/CN109415358B/zh not_active Expired - Fee Related
- 2017-04-26 EA EA201892438A patent/EA036318B1/ru not_active IP Right Cessation
- 2017-04-26 CR CR20180505A patent/CR20180505A/es unknown
- 2017-04-26 US US15/497,565 patent/US10975068B2/en active Active
- 2017-04-26 MX MX2018013143A patent/MX2018013143A/es unknown
- 2017-04-26 AU AU2017255525A patent/AU2017255525A1/en not_active Abandoned
- 2017-04-26 JP JP2018556297A patent/JP6893218B2/ja active Active
- 2017-04-26 BR BR112018071942A patent/BR112018071942A2/pt not_active Application Discontinuation
- 2017-04-26 WO PCT/US2017/029531 patent/WO2017189661A1/en active Application Filing
- 2017-04-26 PE PE2018002176A patent/PE20190150A1/es unknown
- 2017-04-26 EP EP17733165.9A patent/EP3448856B1/en active Active
- 2017-04-26 MA MA044772A patent/MA44772A/fr unknown
- 2017-04-26 KR KR1020187033945A patent/KR20180135962A/ko not_active Application Discontinuation
- 2017-04-26 ES ES17733165T patent/ES2906258T3/es active Active
- 2017-04-27 AR ARP170101078A patent/AR108344A1/es unknown
- 2017-04-27 UY UY0001037213A patent/UY37213A/es unknown
-
2018
- 2018-10-15 IL IL262381A patent/IL262381A/en unknown
- 2018-10-16 PH PH12018502209A patent/PH12018502209A1/en unknown
- 2018-10-25 CL CL2018003044A patent/CL2018003044A1/es unknown
- 2018-10-26 NI NI201800109A patent/NI201800109A/es unknown
- 2018-10-26 SV SV2018005772A patent/SV2018005772A/es unknown
- 2018-10-29 CO CONC2018/0011633A patent/CO2018011633A2/es unknown
- 2018-11-26 EC ECSENADI201888146A patent/ECSP18088146A/es unknown
-
2021
- 2021-02-23 US US17/182,363 patent/US20210221804A1/en active Pending
- 2021-02-23 US US17/182,387 patent/US20210188836A1/en not_active Abandoned
- 2021-02-23 US US17/182,375 patent/US20210198251A1/en not_active Abandoned
-
2022
- 2022-12-19 US US18/084,427 patent/US20230123208A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018011633A2 (es) | 6-aminopiridin-3-il tiazoles como moduladores de rorγt | |
CO2017005014A2 (es) | 4-feniltiazol-2-carboxamida y 4-(piridin-3-il)tiazol-2-carboxamida moduladores del receptor nuclear rorγt | |
UY35084A (es) | MODULADORES DE RORyt DE QUINOLINILO UNIDOS POR METILENO | |
CO7350658A2 (es) | Moduladores de quinolinilo unidos a fenilo de rorgammat | |
CY1122563T1 (el) | ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt | |
DOP2017000120A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
CY1121285T1 (el) | Θειαζολια ως διαμορφωτες toy roryt | |
EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
CO2017004074A2 (es) | Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
NZ738672A (en) | Therapeutic compounds and compositions for treating social disorders and substance use disorders | |
BR112017025263A2 (pt) | método para o tratamento de doença neurológica | |
BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. |